Pushkal Garg sold $621k of ALNY
CMO & EVP Dev & Med Affairs at ALNYLAM PHARMACEUTICALS, INC.. 2,557 shares at an average of $242.92, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +20Trade size$621k at market
- 0Share of holdings soldSold 9.4% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000032, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | AGrant or award Common Stock10b5-1 | +14,137 | $0.00 | $0 | 27,099 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -213 | $242.37 | $52k | 26,886 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -235 | $243.36 | $57k | 26,651 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -158 | $244.41 | $39k | 26,493 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -116 | $245.26 | $28k | 26,377 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -48 | $246.18 | $12k | 26,329 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5 | $247.35 | $1,237 | 26,324 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1 | $248.36 | $248 | 26,323 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -583 | $243.13 | $142k | 25,740 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -273 | $244.43 | $67k | 25,467 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -117 | $245.53 | $29k | 25,350 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -147 | $239.25 | $35k | 25,203 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -343 | $240.92 | $83k | 24,860 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -198 | $241.60 | $48k | 24,662 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -120 | $242.70 | $29k | 24,542 | Mar 5, 2025 |
| Mar 3, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +7,819 | $0.00 | $0 | 7,819 | Mar 5, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 35Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $16M 50,937 shares | -63% | |
| 15Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $3.1M 11,250 shares | -40% | |
| 23Weak | ALNYbuy ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $10k 36 shares | - | |
| 45Moderate | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8,383 36 shares | -100% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $2.2M 7,440 shares | -98% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $2.9M 9,766 shares | -40% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $945k 3,877 shares | -4% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $308k 1,264 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $115k 471 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.